Mirum Pharmaceuticals, INC. 8-K Filing

Ticker: MIRM · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1759425

Sentiment: neutral

Filing Stats: 4,234 words · 17 min read · ~14 pages · Grade level 16.8 · Accepted 2025-12-08 08:00:29

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Form 8-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Generally, the words "anticipate," "estimate," "expect," "project," "intend," "plan," "contemplate," "predict," "forecast," "likely," "believe," "target," "will," "could," "would," "should," "potential," "may," "guidance," "designed" and similar expressions or their negative, may, but are not necessary to, identify forward-looking statements. Such forward-looking statements include, but are not limited to, those regarding the anticipated occurrence, manner and timing of the Mergers and the Private Placement; achievement of the milestones in the Merger Agreement; the payment of additional consideration upon such achievement; brelovitug's ongoing development, including the potential successful results from the pivotal Phase 3 studies for HDV, the potential benefits of brelovitug for patients with HDV and HBV viral infections, the anticipated receipt and timing of data from the studies in the AZURE Phase 3 program, the anticipated costs of developing brelovitug, the estimated prevalence of HDV in the United States, Europe and worldwide, the effects of HDV on patients, the expected worldwide total addressable market for brelovitug in HDV, the ability for the AZURE Phase 3 program to support regulatory filings in the United States and Europe, and the potential submission and timing of regulatory filings for brelovitug, approval of such submissions and the timing for a launch of brelovitug in HDV, if approved; the anticipated receipt and timing of data from the Company's clinical trials; the anticipated timing of an NDA submission to the FDA for the approval of volixibat for the treatment of PSC and the receipt and timing of such approval and any subsequent launch, if approved; and statements about the Company's future financial performance, includin

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 2.1* Agreement and Plan of Merger and Reorganization, dated December 6, 2025, by and among, Mirum Pharmaceuticals, Inc., Bjork Merger Sub I, Inc., Bjork Merger Sub II, LLC, Bluejay Therapeutics, Inc. and Fortis Advisors LLC 4.1 Form of Pre-Funded Warrant 10.1 Form of Subscription Agreement 10.2 Form of Registration Rights Agreement 99.1 Press Release, dated December 8, 2025 99.2 Mirum Corporate Presentation on Potential Acquisition of Bluejay Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Certain portions of this exhibit have been omitted (as marked in brackets) because it is both not material and is the type that the registrant treats as private or confidential. Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mirum Pharmaceuticals, Inc. Date: December 8, 2025 By: /s/ Christopher Peetz Christopher Peetz Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing